2024-12-17 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison & Company Overview:**

Johnson & Johnson is a multinational medical devices, pharmaceuticals, and consumer packaged goods company.

The cumulative return of JNJ (22.97%) significantly underperformed the S&P 500 (VOO) cumulative return (121.78%) over the analyzed period.  The difference is a substantial -98.8%. This places JNJ at the lowest point (0.0 percentile) in the historical range of its relative performance against the S&P 500.  The provided CAGR data shows inconsistent performance, with periods of strong growth and periods of significant decline relative to its market capitalization.  Alpha consistently remains near zero, indicating the stock's returns closely track the market, while Beta shows moderate market sensitivity.

**2. Recent Price Movement:**

* **Closing Price:** $143.85
* **5-Day Moving Average:** $146.52
* **20-Day Moving Average:** $151.18
* **60-Day Moving Average:** $156.36

The stock price is currently below all three moving averages, suggesting a downtrend.

**3. Technical Indicators & Expected Return:**

* **RSI:** 11.24 (Extremely oversold)
* **PPO:** -0.41 (Negative momentum)
* **Relative Divergence (20-day):** -1.2 (Short-term downtrend)

The extremely low RSI and negative PPO values, coupled with the price being below its moving averages and exhibiting a recent short-term downturn, strongly suggest a bearish trend.  The provided expected return of 0.0% for long-term (2+ years) investment indicates that at the current price point, the model does not anticipate significant outperformance against the S&P 500, even with a long-term horizon. The current price of $143.85 does not suggest a recent sharp uptrend or significant rapid downward movement. Further analysis may be needed to determine if this is a potential buying opportunity based on the significantly oversold RSI.

**4. Recent Earnings Analysis:**

The provided earnings data shows inconsistent EPS and relatively flat revenue growth.  While revenue has remained relatively stable around $22B, EPS fluctuates significantly between quarters.  The substantial drop in EPS from $1.95 in Q2 2024 to $1.12 in Q3 2024 warrants further investigation.  Without comparative expectations, it is impossible to definitively identify "beats" or "misses".  Further information is required for a complete analysis of the reported earnings.

**5. Financial Information Analysis:**

* **Revenue:** Revenue has remained relatively stable over the past five quarters, fluctuating only slightly.
* **Profit Margin:** Profit margins are consistently high, averaging around 69%, indicating strong profitability.  A slight decrease is observed in Q4 2023.
* **Equity:** Equity fluctuates slightly.
* **ROE:** Return on equity is highly variable, exhibiting a significant spike in Q3 2023 (36.54%) followed by a sharp decrease in subsequent quarters.  This volatility requires further examination to understand the underlying factors.

The financial data displays a pattern of strong profitability but considerable volatility in key metrics like EPS and ROE.

**6. News and Recent Issues:**

No recent news (within the last two days) or analyst opinions/outlooks were provided.  Without this crucial information, a comprehensive assessment of recent market sentiment is impossible.

**7. Overall Analysis:**

JNJ significantly underperformed the S&P 500 over the analyzed period. Technical indicators point to an oversold condition and a bearish short-term trend.  While profitability remains strong, recent earnings reports show considerable volatility in EPS and ROE. The lack of recent news and analyst opinions hinders a complete evaluation of the current market outlook.  More data is needed, specifically regarding earnings expectations and recent market events, to provide a more comprehensive and confident assessment.  The extremely low RSI, however, may present a buying opportunity for long-term investors with a high risk tolerance, provided further analysis supports such a strategy.

**8. Disclaimer:** This report is for informational purposes only and should not be considered investment advice.  The analysis is based solely on the limited data provided and may not reflect the complete picture.  Conduct thorough research and consult with a qualified financial advisor before making any investment decisions.
